Home › Chronic Kidney Disease › NCT04099992
Mindfulness in Chronic Kidney Disease
Recruiting
Sympatho-inhibition With Mindfulness in Chronic Kidney Disease (MIND-CKD)
Who can join
Ages 40 to 80 · All sexes
Full eligibility criteria
Inclusion Criteria: * stages III and IV CKD as defined by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation * stable renal function (no greater than a decline of eGFR of 1 cc/min/1.73 m2 per month over the prior 3 months) Exclusion Criteria: * severe CKD (eGFR\<15 cc/min) * diabetic neuropathy * autonomic dysfunction * any serious disease that might influence survival * anemia with hemoglobin \<10 g/dL * treatment with central α-agonists or monoamine oxidase (MAO) inhibitors * myocardial infarction or cerebrovascular accident within the past 6 months * uncontrolled hypertension (BP≥170/100 mm Hg) * low BP (BP\<100/50 mm Hg) * bradycardia (HR\<55 beats/min) * ongoing drug or alcohol abuse (defined as \>2 drinks/day in men, and \>1 drink/day in women) * surgery within the past 3 months * adjustment of antihypertensive medications within the past month * pregnancy or plans to become pregnant * psychosis * suicidal ideation * implanted electronic or metallic device such as a pacemaker * implanted hearing aid, bone plate, carotid stent, bone screw at or near the neck * carotid atherosclerosis * concurrent use of another stimulating device such as a transcutaneous electrical nerve stimulation (TENS) unit
About the study
This study will test whether mindfulness meditation (MM) improves sympathetic function in chronic kidney disease (CKD) and whether transcutaneous vagus nerve stimulation (tVNS) optimizes the sympatho-inhibitory effects of mindfulness meditation (MM) and restores autonomic balance in CKD patients.
What is being tested
- Mindfulness-based stress reduction (MBSR) (behavioral)
- Health enhancement program (HEP) (behavioral)
- Transcutaneous Vagus Nerve Stimulation (tVNS) (device)
- Sham-transcutaneous Vagus Nerve Stimulation (tVNS) (device)
Sponsor: Emory University · Participants: 150 · Started: Sep 20, 2019
Contact the study team
- Jeanie Park, MD · Phone: 404-727-2525
- Dana DaCosta · Phone: 404-727-7762
Official record on ClinicalTrials.gov — NCT04099992
Locations in the U.S.
| Georgia | Atlanta VA Medical Center, Atlanta |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.